Evidence map›Paper›PMID 26582596›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2016

A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies.

Kaustav Majumder, Nivedita Arora, Shrey Modi, Rohit Chugh, Alice Nomura, Bhuwan Giri, Rajinder Dawra, Sundaram Ramakrishnan, Sulagna Banerjee, Ashok Saluja and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Modulating tumor mechanics and vascular barriers to enhance chemotherapy efficacy in pancreatic tumors and melanoma.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  3. Review
  4. Article
  5. Orthotopic Models of Pancreatic Cancer to Study PDT.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kaustav MajumderDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA.
Nivedita AroraDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA.
Shrey ModiDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA.
Rohit ChughDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA.
Alice NomuraDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA.
Bhuwan GiriDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA.
Rajinder DawraDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA.
Sundaram RamakrishnanDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA.
Sulagna BanerjeeDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA.
Ashok SalujaDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA.
Vikas DudejaDivision of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN, 55455, USA. dudej001@umn.edu.
University of Minnesota · US

Funding

The Inhibition of HSP70 Induces Apoptosis in Pancreatic Cancer CellsR01CA124723 · NCI · UNIVERSITY OF MINNESOTA · PI GILBOA, ELI, RAMAKRISHNAN, SUNDARAM · 2007 to 2022
$4.5M
Triptolide Augments Death Receptor Mediated Apoptosis in Pancreatic CancerR01CA170946 · NCI · UNIVERSITY OF MINNESOTA · PI SALUJA, ASHOK K · 2012 to 2016
$2.4M
Functional Significance of CD133 in Pancreatic CancerR01CA184274 · NCI · UNIVERSITY OF MINNESOTA · PI BANERJEE, SULAGNA · 2014 to 2018
$1.6M
NCI NIH HHS CA124723NCI NIH HHS R01 CA124723NCI NIH HHS R01 CA170946NCI NIH HHS R01-CA170946NCI NIH HHS R01 CA184274NCI NIH HHS R01-CA184274
6 · The paper itself

Abstract

A valid preclinical tumor model should recapitulate the tumor microenvironment. Immune and stromal components are absent in immunodeficient models of pancreatic cancer. While these components are present in genetically engineered models such as Kras(G12D); Trp53(R172H); Pdx-1Cre (KPC), immense variability in development of invasive disease makes them unsuitable for evaluation of novel therapies. We have generated a novel mouse model of pancreatic cancer by implanting tumor fragments from KPC mice into the pancreas of wild type mice. Three-millimeter tumor pieces from KPC mice were implanted into the pancreas of C57BL/6J mice. Four to eight weeks later, tumors were harvested, and stromal and immune components were evaluated. The efficacy of Minnelide, a novel compound which has been shown to be effective against pancreatic cancer in a number of preclinical murine models, was evaluated. In our model, consistent tumor growth and metastases were observed. Tumors demonstrated intense desmoplasia and leukocytic infiltration which was comparable to that in the genetically engineered KPC model and significantly more than that observed in KPC tumor-derived cell line implantation model. Minnelide treatment resulted in a significant decrease in the tumor weight and volume. This novel model demonstrates a consistent growth rate and tumor-associated mortality and recapitulates the tumor microenvironment. This convenient model is a valuable tool to evaluate novel therapies.

Indexed as

AdenocarcinomaAnimalsAntineoplastic AgentsDiterpenesEpoxy CompoundsFemaleMiceMice, Inbred C57BLMice, TransgenicNeoplasms, ExperimentalOrganophosphatesPancreatic NeoplasmsPhenanthrenesRandom AllocationTumor Microenvironment14-O-phosphonooxymethyltriptolide disodium saltAntineoplastic AgentsDiterpenesEpoxy CompoundsOrganophosphatesPhenanthrenesImmunocompetent mouse modelPancreatic cancerStromaSyngeneic

Identifiers

PMID26582596
PMCPMC5724755
OpenAlexW2181078902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.